Tumor Gene Expression Profiling in Women with Breast Cancer: Test Category: Prognostic

Differences in the expression of specific genes within breast tumors have been associated with risk of recurrence after treatment. Most women with Stage I or II node-negative breast cancer (especially when estrogen-receptor positive and treated with tamoxifen) remain disease-free at 10 years. Inform...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellcross, Cecelia, W. David Dotson
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Evidence on Genomic Tests
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940139/
https://www.ncbi.nlm.nih.gov/pubmed/20877449
http://dx.doi.org/10.1371/currents.RRN1178
Descripción
Sumario:Differences in the expression of specific genes within breast tumors have been associated with risk of recurrence after treatment. Most women with Stage I or II node-negative breast cancer (especially when estrogen-receptor positive and treated with tamoxifen) remain disease-free at 10 years. Information on risk of recurrence could help identify women most likely to benefit from chemotherapy. Several clinically available gene expression profiles (GEP) provide “recurrence risk scores” that are intended to supplement information used by clinicians and patients in treatment decision-making.

Ejemplares similares